ArticleJournal of neuro-oncology2026

Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.

Angelo Dipasquale et al.PubMed ↗Publisher ↗

No numbers read from the abstract.